Moskin Comments on Scandalous Trademarks Decision

Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.

Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."

Foley & Lardner LLP partner Aaron Maguregui commented in The New York Times article, "Hot Dogs for Insomnia? A Kennedy Aide's Start-Up Can Get You a Tax Break," sharing insight on the growing use of medical necessity letters to support tax-advantaged purchases of wellness products.